Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology ...

In a regulatory filing, Tata Capital said the IPO will issue equity shares of face value of ₹10 each, and it will comprise a fresh issue of up to 230 million shares and an offer for sale of equity ...

Tata Capital will be the first company from the Tata Group to launch an IPO since Tata Technologies went public in November 2023. Listen to Story Tata Capital plans IPO, issuing 23 crore new shares ...

A Complete Guide of ASCO GU 2025 for The Community Oncologist In this article ... In this randomized, double-blind, placebo-controlled trial, 230 adult patients were assigned 1:1 to receive either ...

Wright and the 9th Circuit panel both disagreed, saying Grindr was shielded from responsibility for the rapes under Section 230 of the Communications Decency Act of 1996. “This would have been a ...

This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

"We're all in this together." -- Jeremy Stricsek, MD, of Cambridge Health Alliance (CHA) in Massachusetts, after more than 230 CHA clinicians won their union election. "The mechanisms may be ...

The full results were presented during the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2025 Congress. NUBEQA is indicated in the U.S. for the treatment of adult ...

The TALAPRO-2 results will be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco and featured in the ASCO GU official Press Program.

Data from cohort 1 will be presented today at ASCO GU in an oral presentation (Abstract LBA18) by Dr. Neeraj Agarwal, global lead investigator for TALAPRO-2. In Cohort 2, a statistically ...

2 At ASCO GU, Agarwal and colleagues reported final OS data along with “a descriptive update of rPFS, and extended safety follow-up in cohort 1,” according to their abstract. The 805 patients in ...